Beck, D. B. et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N. Engl. J. Med. 383, 2628–2638 (2020). Seminal paper describing VEXAS as a distinct clinical entity caused by UBA1 mutations.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramser, J. et al. Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. Am. J. Hum. Genet. 82, 188–193 (2008).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, T. et al. Genomic and evolutionary classification of lung cancer in never smokers. Nat. Genet. 53, 1348–1359 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beck, D. B. et al. Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA 329, 318–324 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corty, R. W. et al. VEXAS-defining UBA1 somatic variants in 245,368 diverse individuals in the NIH All Of Us cohort. Arthritis Rheumatol. 76, 942–948 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinez Rodriguez, A. et al. Mapping VEXAS-associated and rare UBA1 variants in the United Kingdom: insights from patient cohorts and the general population. Br. J. Haematol. 208, 116–128 (2026).

Article  PubMed  Google Scholar 

Sakuma, M. et al. Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations. Leukemia 39, 2872–2880 (2025). This paper compares clinical manifestations in Met41 and non-Met41 mutations in a large cohort of patients with VEXAS, with higher incidence of severe haematological manifestations in the latter.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maeda, A. et al. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome. Rheumatology 63, 2056–2064 (2024).

Article  CAS  PubMed  Google Scholar 

Barba, T. et al. VEXAS syndrome in a woman. Rheumatology 60, E402–E403 (2021).

Article  PubMed  Google Scholar 

Echerbault, R. et al. Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports. Rheumatology 63, 2694–2700 (2024).

Article  CAS  PubMed  Google Scholar 

Bourguiba, R. et al. Characterizing VEXAS syndrome in women: findings from an international multicenter study. J. Intern. Med. 298, 516–524 (2025).

Article  PubMed  Google Scholar 

Anderson, M. et al. Clinical manifestations of VEXAS syndrome across a broad spectrum of UBA1 mutation burden. Arthritis Rheumatol. 78, 223–230 (2026).

Article  CAS  PubMed  Google Scholar 

Ferrada, M. A. et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 140, 1496–1506 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Georgin-Lavialle, S. et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br. J. Dermatol. 186, 564–574 (2022).

Article  CAS  PubMed  Google Scholar 

Maeda, A. et al. High glucocorticoid dependency and limited therapeutic response in Japanese patients with VEXAS syndrome: a multicentre retrospective study. Mod. Rheumatol. 36, 307–312 (2025).

Article  Google Scholar 

Kirino, Y. et al. Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry. Rheumatology 64, 3872–3878 (2025). Prospective registry study on clinical outcomes in a cohort of patients with VEXAS.

Article  PubMed  Google Scholar 

Hadjadj, J. & Beck, D. VEXAS Syndrome. in GeneReviews [Internet] https://www.ncbi.nlm.nih.gov/books/NBK614471/ (2025).

Turturice, B. A. et al. Disease trajectories and glucocorticoid exposure in VEXAS syndrome treated with cytokine-directed therapies. Ann. Rheum. Dis. 85, 370–378 (2025).

Google Scholar 

Adachi, S. et al. Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome. Rheumatol. Adv. Pract. 8, rkae065 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Mizumaki, H. et al. In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome. Nat. Commun. 16, 4690 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Breillat, P. et al. Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome. Blood 146, 1950–1963 (2025).

Article  CAS  PubMed  Google Scholar 

Kosmider, O. et al. VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nat. Commun. 15, 910 (2024). This paper describes inflammasome activation and immune dysregulation as hallmarks of myeloid-driven inflammation in VEXAS.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rape, M. Ubiquitylation at the crossroads of development and disease. Nat. Rev. Mol. Cell Biol. 19, 59–70 (2018).

Article  CAS  PubMed  Google Scholar 

McGrath, J. P., Jentsch, S. & Varshavsky, A. UBA1: an essential yeast gene encoding ubiquitin-activating enzyme. EMBO J. 10, 227–236 (1991).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganesan S. et al. Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome. Preprint at bioRxiv https://doi.org/10.1101/2024.05.19.594376 (2024). This paper identifies the PERK UPR axis as functional vulnerability in UBA1-mutant cells through single-cell multi-omics profiling.

Magaziner, S. J. et al. The mechanism of cell autonomous inflammation in VEXAS syndrome Is mediated by proteotoxic stress [abstract]. Blood 144, 187 (2024).

Article  Google Scholar 

Collins, J. C. et al. Shared and distinct mechanisms of UBA1 inactivation across different diseases. EMBO J. 43, 1919–1946 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Molteni, R. et al. Mechanisms of hematopoietic clonal dominance in VEXAS syndrome. Nat. Med. 31, 1911–1924 (2025). This paper describes in vitro and in vivo humanized models of VEXAS and exploits them to describe how UBA1-mutant haematopoietic clones may acquire dominance over wild-type haematopoiesis.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdellatif, H. Circulating CD34+ hematopoietic stem/progenitor cells paralleled with level of viremia in patients chronically infected with hepatitis B virus. Regen. Med. Res. 6, 1 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Gutierrez-Rodrigues, F. et al. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood J. 142, 244–259 (2023). This paper describes the heterogeneous interplay between CHIP mutations in patients with VEXAS and their correlation with clinical outcomes.

CAS  Google Scholar 

Wu, Z. et al. Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS. Cell. Rep. Med. 4, 101160 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodrigues, F. et al. VEXAS anemia is a mosaic erythroblastopenia. Blood 147, 1178–1190 (2026).

Article  CAS  Google Scholar 

Narendra, V. K. et al. Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome. Nature 649, 1273–1281 (2026).

Article  PubMed  Google Scholar 

Breillat, P. et al. Inflammatory cell death and monocyte dysfunction in VEXAS syndrome. Blood https://doi.org/10.1182/blood.2025031593 (2026).

Article